{"product_id":"lucielace-elacestrant","title":"LuciElace (Elacestrant)","description":"\u003ch2\u003eAbout Elacestrant\u003c\/h2\u003e\u003cp\u003eAbout Elacestrant  is a selective estrogen receptor degrader (SERD) used in the treatment of breast cancer. Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors, which are the biological targets of endogenous estrogens like estradiol. \u003c\/p\u003e\u003cp\u003eElacestrant is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one other line of endocrine therapy.\u003c\/p\u003e\u003ch3\u003eBreast Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for men or postmenopausal women with estrogen receptor positive (ER+), HER\u003csub\u003e2\u003c\/sub\u003e-negative, ESR\u003csub\u003e1\u003c\/sub\u003e-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy\u003c\/p\u003e\u003cp\u003e345 mg PO qDay with food until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose reduction recommendations for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 258 mg qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 172 mg qDay\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if dose reduction \u0026lt;172 mg\/day required\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eModifications for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 1: Continue at current dose level\u003c\/li\u003e\n\u003cli\u003eGrade 2: Consider dose interruption until recovery to Grade ≤1 or baseline, then resume at same dose\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt dose until recovery to Grade ≤1 or baseline, then resume at next lower dose\u003c\/li\u003e\n\u003cli\u003eIf Grade 3 toxicity recurs, interrupt until recovery to Grade ≤1 or baseline, then resume elacestrant reduced by another dose level\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt dose until recovery to Grade ≤1 or baseline, then resume at next lower dose\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if Grade 4 or intolerable adverse reaction recurs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment recommended\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh B): Reduce dose to 258 mg qDay\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Avoid use; not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955538987,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1017.jpg?v=1787022234","url":"https:\/\/xomeds.com\/products\/lucielace-elacestrant","provider":"XOMEDS","version":"1.0","type":"link"}